Description
Axamon Pharmacodynamics
Axamon® is a reversible cholinesterase inhibitor, directly stimulates impulse conduction in the neuromuscular synapse and in the central nervous system (CNS) due to blockade of membrane potassium channels. It enhances the effect on smooth muscles not only of acetylcholine but also of adrenaline, serotonin, histamine and oxytocin.
Axamon® has the following pharmacological effects:
– Improves and stimulates impulse conduction in the nervous system and neuromuscular transmission;
– Improves conduction in the peripheral nervous system that is impaired due to trauma, inflammation, effects of local anesthetics, some antibiotics, potassium chloride, etc;
– increases smooth muscle organ contractility under the influence of agonists of acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, except potassium chloride;
– Improves memory, inhibits the progressive development of dementia.
Does not have teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic effects. It does not affect the endocrine system.
Indications
Peripheral nervous system disorders: mono- and polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of different etiology;
– CNS diseases: bulbar paralysis and paresis;
recovery period of organic lesions of the CNS, accompanied by movement disorders;
– bowel atony.
Contraindications .
Hypersensitivity to any drug component, epilepsy, extrapyramidal disorders with hyperkinesias, angina pectoris, bradycardia, bronchial asthma, mechanical obstruction of the intestines or urinary tract, vestibular disorders, acute gastric or duodenal ulcer, pregnancy (drug increases uterine tone) and lactation, children age less than 18 years (no systematic data on its use are available).
With caution when: gastric and duodenal ulcer, thyrotoxicosis, diseases of the cardiovascular system, obstructive diseases of the respiratory system in the anamnesis or acute respiratory diseases.
If you have one of the above diseases, be sure to consult your doctor before taking the drug.
Administration during pregnancy and breast-feeding
Due to a lack of studies, use during pregnancy and lactation is not recommended.
Dosage and administration
- Subcutaneously or intramuscularly. Doses and duration of treatment are determined individually depending on the severity of the disease.
- Diseases of the peripheral nervous system:
– mono- and polyneuropathies of different genesis, polyradiculopathies: subcutaneously or intramuscularly 5-15 mg 1-2 times daily, 10-15 days course (in severe cases – up to 30 days); further treatment is continued with tablet form of the drug;
– myasthenia gravis and myasthenic syndrome: subcutaneously or intramuscularly 15-30 mg 1-3 times a day with subsequent change to tablet form. Total course of treatment is 1-2 months. If necessary, treatment may be repeated several times with a break between courses of 1-2 months. - CNS diseases
– bulbar paralysis and paresis: subcutaneously or intramuscularly 5-15 mg 1-2 times a day, 10-15 days course; then, if possible, switch to tablet form;
– The recovery period of organic lesions of the central nervous system accompanied by motor disorders: intramuscularly 10-15 mg 1-2 times a day, course of up to 15 days; then, if possible, switch to tablet form. - Treatment and prevention of bowel atony: initial dose – 10-15 mg 1-2 times a day for 1-2 weeks.
